Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of intravenous SNDX-6352 in healthy volunteers
NL-OMON42865Phase 1Active, not recruiting
- Sponsor
- Syndax Pharmaceuticals
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of axatilimab in cancer (7 arms), sponsored by Syndax Pharmaceuticals. Primary endpoint: Safety and tolerability. Started Oct 2016; status: active, not recruiting.
02
Drugs
axatilimab
03
Conditions
cancer
Beyond the preview
Go deeper on NL-OMON42865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42865.